drugset / Trial / NCT00569387

Vaccine Study for Surgically Resected Pancreatic Cancer

NCT00569387 ↗

Phase 2 Completed 73 enrolled NewLink Genetics Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with chemotherapy and chemoradiation.

Timeline

Start
2007-12
Primary completion
2011-03
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Algenpantucel-L Vaccine 1e+08 cells Intravenous